Rhumbline Advisers Has $217,000 Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Rhumbline Advisers boosted its stake in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 12.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 34,299 shares of the company’s stock after purchasing an additional 3,911 shares during the quarter. Rhumbline Advisers’ holdings in Fennec Pharmaceuticals were worth $217,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. grew its stake in Fennec Pharmaceuticals by 18.7% during the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after acquiring an additional 2,330 shares in the last quarter. Barclays PLC grew its stake in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after acquiring an additional 22,951 shares in the last quarter. State Street Corp grew its stake in shares of Fennec Pharmaceuticals by 2.2% in the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after buying an additional 7,053 shares in the last quarter. Finally, Advantage Alpha Capital Partners LP bought a new stake in shares of Fennec Pharmaceuticals in the 3rd quarter valued at approximately $264,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Fennec Pharmaceuticals Stock Down 11.2 %

Shares of Fennec Pharmaceuticals stock opened at $6.11 on Tuesday. The stock has a market capitalization of $168.40 million, a P/E ratio of -61.09 and a beta of 0.36. The stock has a 50 day moving average price of $6.39 and a two-hundred day moving average price of $5.61. Fennec Pharmaceuticals Inc has a 12-month low of $3.96 and a 12-month high of $11.49.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on FENC. Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th. Wedbush reissued an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th.

Insiders Place Their Bets

In other news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $6.08, for a total transaction of $60,800.00. Following the completion of the transaction, the director now directly owns 83,863 shares in the company, valued at $509,887.04. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 31,186 shares of company stock valued at $203,389 over the last 90 days. 10.98% of the stock is currently owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.